Current therapies and new developments in NASH
Non-alcoholic steatohepatitis is becoming the most important aetiology for advanced liver
disease. There has been important progress in the field in recent years and the complexity of …
disease. There has been important progress in the field in recent years and the complexity of …
[HTML][HTML] Artificial intelligence in liver diseases: Improving diagnostics, prognostics and response prediction
D Nam, J Chapiro, V Paradis, TP Seraphin, JN Kather - Jhep Reports, 2022 - Elsevier
Clinical routine in hepatology involves the diagnosis and treatment of a wide spectrum of
metabolic, infectious, autoimmune and neoplastic diseases. Clinicians integrate qualitative …
metabolic, infectious, autoimmune and neoplastic diseases. Clinicians integrate qualitative …
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
BA Davison, SA Harrison, G Cotter, N Alkhouri… - Journal of …, 2020 - Elsevier
Background & Aims Liver biopsies are a critical component of pivotal studies in non-
alcoholic steatohepatitis (NASH), constituting inclusion criteria, risk stratification factors and …
alcoholic steatohepatitis (NASH), constituting inclusion criteria, risk stratification factors and …
Clinical applications of artificial intelligence—an updated overview
Ș Busnatu, AG Niculescu, A Bolocan… - Journal of clinical …, 2022 - mdpi.com
Artificial intelligence has the potential to revolutionize modern society in all its aspects.
Encouraged by the variety and vast amount of data that can be gathered from patients (eg …
Encouraged by the variety and vast amount of data that can be gathered from patients (eg …
[HTML][HTML] Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH
NV Naoumov, D Brees, J Loeffler, E Chng, Y Ren… - Journal of …, 2022 - Elsevier
Background & Aims Liver fibrosis is a key prognostic determinant for clinical outcomes in
non-alcoholic steatohepatitis (NASH). Current scoring systems have limitations, especially in …
non-alcoholic steatohepatitis (NASH). Current scoring systems have limitations, especially in …
[PDF][PDF] A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH
A Taylor‐Weiner, H Pokkalla, L Han, C Jia, R Huss… - …, 2021 - Wiley Online Library
Background and Aims Manual histological assessment is currently the accepted standard for
diagnosing and monitoring disease progression in NASH, but is limited by variability in …
diagnosing and monitoring disease progression in NASH, but is limited by variability in …
Artificial intelligence in gastroenterology: A state-of-the-art review
PT Kröner, MML Engels, BS Glicksberg… - World journal of …, 2021 - pmc.ncbi.nlm.nih.gov
The development of artificial intelligence (AI) has increased dramatically in the last 20 years,
with clinical applications progressively being explored for most of the medical specialties …
with clinical applications progressively being explored for most of the medical specialties …
Application of artificial intelligence for the diagnosis and treatment of liver diseases
JC Ahn, A Connell, DA Simonetto, C Hughes… - …, 2021 - Wiley Online Library
Modern medical care produces large volumes of multimodal patient data, which many
clinicians struggle to process and synthesize into actionable knowledge. In recent years …
clinicians struggle to process and synthesize into actionable knowledge. In recent years …
Hybrid XGBoost model with hyperparameter tuning for prediction of liver disease with better accuracy
BACKGROUND Liver disease indicates any pathology that can harm or destroy the liver or
prevent it from normal functioning. The global community has recently witnessed an …
prevent it from normal functioning. The global community has recently witnessed an …
[HTML][HTML] Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models
MA Heinrich, AMRH Mostafa, JP Morton… - Advanced drug delivery …, 2021 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive type of cancer with
an overall survival rate of less than 7-8%, emphasizing the need for novel effective …
an overall survival rate of less than 7-8%, emphasizing the need for novel effective …